Drug Profile
Terbogrel
Alternative Names: BIBV 308SELatest Information Update: 13 Oct 2014
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Pyridines
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane A2 synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Peripheral vascular disorders; Pulmonary hypertension; Thrombosis
Most Recent Events
- 13 Oct 2003 A clinical study has been added to the adverse events and Vascular Disorders pharmacodynamics sections
- 13 Oct 2003 No development reported - Phase-II for Peripheral vascular disorders in Europe (unspecified route)
- 13 Oct 2003 No development reported - Phase-II for Peripheral vascular disorders in USA (unspecified route)